As we observed PD-1 blockade on tumor-infiltrating lymphocytes (TILs) and Tim-3 upregulation during resistance to the combination therapy with anti-PD-1 antibodies and the Anchored GM-CSF vaccine (day 26), we treated mice with an anti-Tim-3 antibody at this stage to investigate whether Tim-3 blockade can provide additional benefit against tumors (Figure 1B). The gene discussed is CSF2; the disease is neoplasm.